– ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies.
– Rob Nelsen, ARCH co-founder and Managing Director, stated: “We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system. ARCH intends to continue driving the healthcare revolution.”
– Fund XIII will focus on founding and investing in companies that prevent, detect, and cure diseases.
– Investments from Fund XIII to date include Arsenal Biosciences, Inc., Metsera, Mirador Therapeutics, and Xaira Therapeutics.
– Kristina Burow, ARCH Managing Director, said: “ARCH is first and foremost a company builder; we foster innovation at scale to develop new technologies and medicines as rapidly as possible.”
– ARCH’s goal is to continue driving innovation to benefit patients and catalyze the next healthcare revolutions.
– Keith Crandell, ARCH co-founder and Managing Director, remarked: “ARCH has a long history of identifying the top forward-looking trends in life sciences R&D and the individuals driving truly breakthrough scientific hypotheses.”
– Fund XIII follows the $2.975 billion Fund XII, announced in June 2022.
– ARCH’s Managing Directors include Robert Nelsen, Keith Crandell, Kristina Burow, Mark McDonnell, Steve Gillis, and Paul Berns.
– ARCH Venture Partners creates and invests in groundbreaking life science and technology companies, specializing in commercializing technologies from academic institutions, corporate research groups, and national laboratories.
